Methasan

Methadone, the active ingredient in Methasan, is a synthetic opioid presented as an oral tablet for oral use. It is indicated for the treatment of opioid dependence and for the management of chronic pain in adult patients, providing long‑acting analgesic control.

GNH USA supplies Methasan as a licensed, Good Distribution Practice‑compliant pharmaceutical product, delivering to hospitals, pharmacies and clinics worldwide through regulated channels and supporting import documentation for international markets. The company adheres to stringent quality standards and provides technical assistance for safe handling.

Methadone is a synthetic opioid used in the management of opioid dependence and chronic pain.

Opioid dependence: reduces withdrawal symptoms and cravings, supporting maintenance therapy. Chronic pain: provides long‑acting analgesia for persistent moderate to severe pain. Detoxification: facilitates supervised opioid tapering in clinical settings. Palliative care: offers sustained pain relief for terminal patients.

Methadone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel motility. - Dizziness: feeling light‑headed or unsteady. - Sweating: excessive perspiration. - Drowsiness: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: risk of cardiac arrhythmias. - Severe hypotension: marked drop in blood pressure. - Adrenal insufficiency: impaired cortisol production. - Seizures: rare convulsive episodes.

When prescribing Methasan, clinicians should observe several safety measures.

Dose titration: adjust gradually under medical supervision to minimize overdose risk. Cardiac monitoring: obtain baseline ECG and monitor QT interval. Drug dependence: assess for potential misuse before initiating therapy. Pregnancy and lactation: evaluate risks versus benefits; use only if clearly needed. Concomitant CNS depressants: avoid or use with caution due to additive respiratory depression. Store at ambient temperature: keep below 25°C, in original container, protect from moisture and light.

Methasan can interact with several medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase methadone plasma levels, risk of toxicity. - QT‑prolonging agents (e.g., quinidine): additive risk of cardiac arrhythmia. - Respiratory depressants (e.g., benzodiazepines): synergistic respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Anticholinergics: may worsen constipation. - Alcohol: can enhance sedative effects.